Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 1

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 royalty revenue17,060 1 Revenue154,883 141,006 Cost of products and services revenue49,438 48,092 Gross profit105,445 92,914 Operating expenses:Research and development64,245 68,638 Selling, general and administrative89,728 85,774 Gain on settlement(9,200)— Total operating expenses144,773 154,412 Loss from operations(39,328)(61,498)Other income (expense):Interest income3,686 4,736 Interest expense— (1)Other income (expense), net2,136 (1,040)Total other income5,822 3,695 Loss before provision for income taxes(33,506)(57,803)Provision for income taxes852 2,146 Net loss$(34,358)$(59,949)Net loss per share, basic and diluted$(0.28)$(0.50)Weighted-average shares used to compute net loss per share, basic and diluted122,606,091 119,394,180 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

10x Genomics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In thousands)

Three Months EndedMarch 31,20252024Net loss$(34,358)$(59,949)Other comprehensive income (loss), net of tax:Unrealized gains (losses) on available-for-sale marketable securities(20)136 Foreign currency translation adjustment146 (163)Other comprehensive income (loss), net of tax126 (27)Comprehensive loss$(34,232)$(59,976)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

10x Genomics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share data)Common StockAdditional Paid-inCapitalAccumulatedDeficitAccumulatedOther ComprehensiveIncome (Loss)TotalStockholders’EquitySharesAmountBalance as of December 31, 2024122,291,837 $2 $2,177,672 $(1,467,047)$(493)$710,134 Issuance of Class A common stock related to equity awards841,913 — 422 — — 422